The Efficacy of Lamotrigine and Levetiracetam Therapy on Serum Lipid Profile in Epilepsy Patients

Basit Öğe Kaydı
dc.authoridKamisli, Ozden/0000-0003-1114-7860
dc.authoridKamisli, Ozden/0000-0003-1114-7860
dc.authoridozcan, abdulcemal/0000-0002-6759-7556
dc.authoridKamisli, Suat/0000-0003-4281-3301
dc.authorwosidKamisli, Suat/JZT-8388-2024
dc.authorwosidKamisli, Ozden/JVZ-0145-2024
dc.authorwosidKamisli, Ozden/AAA-6553-2020
dc.authorwosidozcan, abdulcemal/B-1348-2008
dc.authorwosidKamisli, Suat/JVN-4663-2024
dc.authorwosidKamisli, Suat/AAC-2706-2021
dc.contributor.authorKamisli, Ozden
dc.contributor.authorKaplan, Yuksel
dc.contributor.authorKamisli, Suat
dc.contributor.authorBakir, Meryem
dc.contributor.authorOzcan, Cemal
dc.date.accessioned2024-08-04T21:02:03Z
dc.date.available2024-08-04T21:02:03Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives: We aimed to investigate the efficacy of two new generation antiepileptics, lamotrigine (LTG) and levetiracetam (LEV), on serum lipid levels, since they are reported to be as effective as classical antiepileptics but with fewer side effects. Methods: We analyzed the files of all epileptic patients who were registered at Inonu University Faculty of Medicine, Turgut Ozal Medical Center, Neurology Department between April 2009 - May 2011 retrospectively. Patients treated with LTG and LEV monotherapy were found and total cholesterol (TC), triglyceride, low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) were measured. The patients' data were compared with a control group. Results: Twenty-one patients treated with LTG and 20 patients treated with LEV were included in this study. TC, triglycerides, LDL, VLDL, and HDL values were compared with 21 healthy control subjects. TC, triglycerides, LDL, VLDL, and HDL values showed no statistically significant differences between groups. Conclusion: Neither LEV nor LTG, which are new generation antiepileptics, affected blood lipid levels. We consider that they are safe to use in patients, especially those with atherosclerosis risk.en_US
dc.identifier.doi10.5505/epilepsi.2011.57442
dc.identifier.endpage57en_US
dc.identifier.issn1300-7157
dc.identifier.issue2en_US
dc.identifier.startpage53en_US
dc.identifier.urihttps://doi.org/10.5505/epilepsi.2011.57442
dc.identifier.urihttps://hdl.handle.net/11616/104433
dc.identifier.volume17en_US
dc.identifier.wosWOS:000408823900003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherKare Publen_US
dc.relation.ispartofEpilepsien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpilepsyen_US
dc.subjectlamotrigineen_US
dc.subjectlevetiracetamen_US
dc.subjectlipiden_US
dc.titleThe Efficacy of Lamotrigine and Levetiracetam Therapy on Serum Lipid Profile in Epilepsy Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu